MedTrace Logo

Investigation of Antibody and Immune Responses to SARS-CoV-2 Proteins in COVID-19 Patients

NCT04465981 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-08-27

No results posted yet for this study

Summary

SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has negatively impacted global health and requires more research to develop better tests and to improve disease treatment.

The purpose of this research is to aid in the testing effort by collecting samples from people who have been diagnosed with COVID-19 or are suspected of having COVID-19. Samples you provide will be used investigationally by INanoBio to develop a test to determine when antibodies against various SARS-CoV-2 proteins are detectable.

Up to approximately 80 subjects of all ages with either a suspected or lab-confirmed diagnosis of COVID-19 will take part in this research.

Conditions

Interventions

DIAGNOSTIC_TEST

Sampling

Test is to validate the utility of INanoBio's automated protein arrays in detecting antibodies against SARS-CoV-2 proteins.

Sponsors & Collaborators

  • TMC HealthCare

    collaborator OTHER

  • INanoBio Inc.

    lead INDUSTRY

Principal Investigators

  • Katherine Scott · TMC HealthCare

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-03
Primary Completion
2022-06-30
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04465981 on ClinicalTrials.gov